5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market.

Let's take a closer look at five of this past week's biggest sinkers.

Company

Nov. 9

Weekly Loss

My Watchlist

James River Coal (Nasdaq: JRCC  )

$2.70

(40%)

Add

Molycorp (NYSE: MCP  )

$7.50

(24%)

Add

VIVUS (Nasdaq: VVUS  )

$10.84

(24%)

Add

Universal Display (Nasdaq: PANL  )

$24.41

(22%)

Add

NII Holdings (Nasdaq: NIHD  )

$6.13

(21%)

Add

Source: Barron's.

Coal miners took a hit after President Obama was reelected, and James River Coal suffered the most. Coal producers were already hurting, and James River Coal is in a very challenging financial position these days.

Molycorp posted healthy growth in its latest quarter, but the rare-earth minerals specialist fell to Earth after revealing a formal SEC investigation into the company's public disclosures.

VIVUS is off to a bad start with its anti-obesity drug. In its first quarter since Qsymia has been made available, revenue barely topped $40,000. Analysts were expecting revenue of roughly $300,000. The treatment was only available during the last 10 days of the month, but it's still a disappointing figure. There are also concerns that those who are getting prescriptions for Qsymia are balking at the price and not getting those orders filled.

Universal Display took a hit after the OLED pioneer posted weak revenue growth, surprised investors with a loss when they were expecting a small quarterly profit, and hosed down its revenue guidance for the year.

NII Holdings hung up on investors after the wireless carrier offering the Nextel brand in Brazil offered up disappointing quarterly results. NII's substantial decline in mobile phone accounts there also didn't help.

Ready for a bounce
The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand-new premium research service. It's such an important story that we have our top health care writer on the job, so make sure to secure a copy today by clicking here now.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2107507, ~/Articles/ArticleHandler.aspx, 11/23/2014 10:20:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement